摘要
目的:检测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者外周血Lunx mRNA表达,探讨其诊断NSCLC微转移、评估预后和化疗疗效的价值。方法:荧光定量PCR法测定66例NSCLC患者和40例良性肺疾病患者外周血Lunx mRNA表达。肺癌组患者随访1~40个月,了解Lunx mRNA表达与生存期的关系,并对其中50例Ⅲ~Ⅳ期NSCLC患者化疗2周期后进行疗效评价以了解其与Lunx基因表达的关系。结果:肺癌患者外周血Lunx mRNA阳性率为57.6%,中位拷贝数为48 copies/ml;良性肺疾病中则无表达。Ⅲ、Ⅳ期肺癌患者外周血Lunx mRNA阳性率(59.3%,88.9%)均明显高于Ⅰ~Ⅱ期患者(18.8%)(P<0.01),Lunx mRNA阳性表达的患者总体生存期明显低于阴性表达者(P<0.01),但其表达与化疗疗效则无明显关系(P>0.05)。结论:外周血Lunx mRNA表达对判断肺癌患者预后具有较大的价值。
Objective:To study the value of the expression of Lunx mRNA in the peripheral blood in detecting the micrometastasis in patients with non-small cell lung cancer(NSCLC)and assessing the prognosis and efficacy of chemotherapy.Methods:Fluorescence quantitative polymerase chain reaction(PCR) was used to detect the expression of Lunx mRNA in the peripheral blood samples from 66 patients with NSCLC and 40 patients with benign pulmonary lesions.The NSCLC patients the cases were followed up for 1 to 40 months,and the relationship between the expression of Lunx and the survival rate of the patients were observed.The objective response of 50 NSCLC patients receiving chemotherapy was evaluated every two cycles.Results:The positive expression of Lunx mRNA was 57.6% in the peripheral blood of patients with NSCLC.The median of copy number was 48 copies /ml.Significant difference of the expression level of Lunx was found in different TNM stages of the lung cancer.No patients with benign pulmonary disease showed positive expression of Lunx mRNA.The overall survival rate in patients with positive expression of Lunx mRNA was obviously lower than that with negative expression(P0.01).But the expression was not related to the efficacy of chemotherapy(P0.05).Conclusions:The expression of Lunx mRNA in the peripheral blood has great predictive value for the prognosis of patients with NSCLC.
出处
《蚌埠医学院学报》
CAS
2010年第4期355-357,360,共4页
Journal of Bengbu Medical College
关键词
肺肿瘤
荧光定量聚合酶链反应
肺特异性X蛋白
微转移
lung neoplasms
fluorescent quantitation polymerase chain reaction
Lunx
micrometastasis